drugset / Trial / NCT06634849
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
NaSingle-groupOpen-labelTreatment
Summary
This open label, dose escalation module will evaluate the safety, tolerability, PK, PD, and preliminary efficacy of PTT-4256 in participants with solid tumours using a combination of accelerated dose titration (ADT) and Bayesian Optimal Interval (BOIN) design.
Timeline
- Start
- 2024-11-04
- Primary completion
- 2027-04-30
- Completion
- 2027-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PTT-4256 | Unknown | 10 mg | Oral |
| Subject | PTT-4256 | Unknown | 20 mg | Oral |
| Subject | PTT-4256 | Unknown | 40 mg | Oral |
| Subject | PTT-4256 | Unknown | 80 mg | Oral |
| Subject | PTT-4256 | Unknown | 160 mg | Oral |
| Subject | PTT-4256 | Unknown | 300 mg | Oral |